Anti-EDAR antibody (50-130 aa) (STJ190407)

SKU:
STJ190407

Current Stock:
Host: Rabbit
Applications: WB/ELISA
Reactivity: Human/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Tumor necrosis factor receptor superfamily member EDAR (50-130 aa) is suitable for use in Western Blot and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-2000
ELISA 1:5000-20000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: EDAR
Gene ID: 10913
Uniprot ID: EDAR_HUMAN
Immunogen Region: 50-130 aa
Specificity: EDAR Polyclonal Antibody detects endogenous levels of protein.
Immunogen: Synthesized peptide derived from the human protein at the amino acid range 50-130
Function Receptor for EDA isoform A1, but not for EDA isoform A2. Mediates the activation of NF-kappa-B and JNK. May promote caspase-independent cell death.
Protein Name Tumor Necrosis Factor Receptor Superfamily Member Edar
Anhidrotic Ectodysplasin Receptor 1
Downless Homolog
Eda-A1 Receptor
Ectodermal Dysplasia Receptor
Ectodysplasin-A Receptor
Database Links Reactome: R-HSA-5669034
Cellular Localisation Membrane
Single-Pass Type I Membrane Protein
Alternative Antibody Names Anti-Tumor Necrosis Factor Receptor Superfamily Member Edar antibody
Anti-Anhidrotic Ectodysplasin Receptor 1 antibody
Anti-Downless Homolog antibody
Anti-Eda-A1 Receptor antibody
Anti-Ectodermal Dysplasia Receptor antibody
Anti-Ectodysplasin-A Receptor antibody
Anti-EDAR antibody
Anti-DL antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance